USD10
EDIT Shares
About Editas MedicineEditas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary ene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
USD10
EDIT Shares
About Editas MedicineEditas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary ene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
Stats
TRADING WINDOW
Closed
OPENS AT
Mar 26 at 1:30 PM GMT+0
MARKET CAP
$220.21M
OPEN PRICE
Not enough data
LOW (1Y)
$0.9101
HIGH (1Y)
$4.54
LOW (24H)
$2.25
HIGH (24H)
$2.38
VOLUME (24H)
$139.00
99.99%
Price history
Time | Price | Change |
|---|---|---|
Today | Not enough data | Not enough data |
1 Day | $2.35 | |
1 Week | $2.31 | |
1 Month | $2.15 | |
1 Year | $1.30 |